| Similar Articles |
|---|
 |
American Family Physician
March 15, 2002
Stephen K. Lane & Joseph W. Gravel, Jr. |
Clinical Utility of Common Serum Rheumatologic Tests Many serum rheumatologic tests have been available for fewer than 10 years. As a result, some physicians are not fully aware of the indications, sensitivity, specificity, cost and clinical utility of these tests...   |
American Family Physician
July 15, 2006
Junnila & Cartwright |
Chronic Musculoskeletal Pain in Children: Part II. Rheumatic Causes Primary care physicians should have a working knowledge of rheumatic diseases of childhood that manifest primarily as musculoskeletal pain. Children with juvenile rheumatoid arthritis can present with painless joint inflammation and may have normal results on rheumatologic tests. |
American Family Physician
July 1, 2006
Junnila & Cartwright |
Chronic Musculoskeletal Pain in Children: Part I. Initial Evaluation Musculoskeletal pain can be difficult for children to characterize. A logical and consistent approach to diagnosis is recommended, with judicious use of laboratory and radiologic testing. |
American Family Physician
September 15, 2003
Richie & Francis |
Diagnostic Approach to Polyarticular Joint Pain Polyarticular joint pain (i.e., pain in more than four joints) poses a diagnostic challenge because of the extensive differential diagnosis. Consequently, family physicians need to keep the diagnosis open in evaluating patients who present with pain in multiple joints. |
Nursing
August 2009
Pullen et al. |
Putting a face on systemic lupus erythematosus In this article, we'll tell you how to assess a patient for SLE and what to teach her about managing this chronic disorder. |
American Family Physician
April 15, 2002
Rajani Katta |
Cutaneous Sarcoidosis: A Dermatologic Masquerader Sarcoidosis is a multisystem disease that may involve almost any organ system; therefore, it results in various clinical manifestations. Cutaneous sarcoidosis occurs in up to one third of patients with systemic sarcoidosis. Recognition of cutaneous lesions is important... |
Chemistry World
March 15, 2011
Sarah Houlton |
Benlysta breaks 50 year Lupus drug drought The first new treatment for lupus erythematosus in half a century has been approved by the US Food and Drug Administration |
Chemistry World
November 4, 2009
Phil Taylor |
New treatment hope for lupus patients GlaxoSmithKline and Human Genome Sciences' Benlysta (belimumab), works by blocking the production of autoantibodies by plasma B-cells, the immune system's primary antibody-producing cells. |
American Family Physician
November 1, 2005
Eddie Needham |
Management of Acute Renal Failure Acute renal failure is an acute loss of kidney function that occurs over days to weeks and results in an inability to appropriately excrete nitrogenous wastes and creatinine. In spite of this rapid decline in kidney function, patients with acute renal failure often have few symptoms. |
American Family Physician
September 15, 2002
Patel & Lundy |
Ocular Manifestations of Autoimmune Disease Because a number of these diseases may initially present with ocular symptoms, physicians should maintain a high index of suspicion to make a timely diagnosis. A thorough ophthalmic examination should be completed. |
The Motley Fool
July 20, 2009
Brian Orelli |
Overnight Triple! Yee-Haw! The joys of owning biotech companies. The latest beneficiary, Human Genome Sciences, is up more than 220% today because Benlysta, their new drug for lupus, works. |
The Motley Fool
October 5, 2005
Stephen D. Simpson |
Lupus Trials Spook Investors Lupus is a high-risk, high-reward indication, and today's disappointing trial results aren't the end of the story for Human Genome Sciences. Aggressive and experienced investors might want to take a look at this one, but this is clearly not a stock for the faint of heart. |
The Motley Fool
April 30, 2008
Brian Lawler |
A Tale of 2 DNA Drugs More trouble for Genentech's No. 2 product, the systemic lupus treatment Rituxan. |
The Motley Fool
June 12, 2009
Brian Orelli |
Where Good Drugs Go to Die Human Genome Sciences has the potential to pop if Benlysta's phase 3 trials are a success, but tread lightly, history is not on their side. |
Nursing
March 2012
Daniel A. Hussar |
New Drugs 2012: part I In this article, you'll learn about 11 recently approved drugs. |
Chemistry World
September 25, 2013
Phillip Broadwith |
Nanobody inflammation drug attracts Abbvie Belgian biotech firm Ablynx has agreed a global licensing deal with Abbvie for its nanobody drug candidate ALX-0061. |
The Motley Fool
October 26, 2011
Brian Orelli |
Down 20%: Benylsta Not Ramping Fast Enough Sales of Human Genome Sciences' new lupus drug Benylsta continues to grow -- just not fast enough to keep investors interest. |
The Motley Fool
September 20, 2007
Brian Orelli |
Teva's Disappointing Phase 2 Results Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial. Investors, take note. |
The Motley Fool
March 9, 2010
Brian Orelli |
The Opportunity That Wasn't Roche and Biogen Idec are suspending development of ocrelizumab for rheumatoid arthritis because patients are coming down with opportunistic infections. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Lupus: How Big will Benlysta Become? Human Genome Sciences/GSK's Benlysta (belimumab) was approved by an FDA advisory committee in November -- to the cheers of many patients who had testified to their need of the novel therapy. |
The Motley Fool
December 30, 2011
Brian Orelli |
A Bad Year for the 6,300% Miracle Human Genome Sciences falls from grace. |
Chemistry World
February 4, 2009
Matt Wilkinson |
GSK targets autoimmune biologics GSK recently signed seven drug development deals that could see the company release a suite of drugs to treat inflammatory diseases ranging from rheumatoid arthritis to lupus. |
Chemistry World
February 4, 2014
Phillip Broadwith |
Merck & Co doubles up on Ablynx research deal This collaboration will focus on nanobodies (antibody fragments) directed against cancer. |
The Motley Fool
September 30, 2011
Brian Orelli |
We Don't Care if It's the First Lupus Drug in 50 Years The U.K.'s National Institute for Health and Clinical Excellence declines Glaxo and HGS' Benlysta. |
The Motley Fool
October 30, 2009
Brian Orelli |
Earnings? Yawn. Trial Data? Moving! For Human Genome Sciences investors, the anticipation is frightening. |
Chemistry World
July 20, 2012
Andrew Turley |
GSK secures $3.6bn HGS deal After months of wrangling, GlaxoSmithKline has found enough common ground with Human Genome Sciences for the two to sign up to a $3.6 billion takeover deal. |
